• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Remdesivir and COVID-19.

作者信息

Wang Lei-Yun, Cui Jia-Jia, Ouyang Qian-Ying, Zhan Yan, Guo Cheng-Xian, Yin Ji-Ye

机构信息

Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410078, China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China; National Clinical Research Center for Geriatric Disorders, Changsha, Hunan, China.

Center of Clinical Pharmacology, the Third Xiangya Hospital, Central South University, Changsha, China.

出版信息

Lancet. 2020 Oct 3;396(10256):953-954. doi: 10.1016/S0140-6736(20)32019-5.

DOI:10.1016/S0140-6736(20)32019-5
PMID:33010833
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7529377/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7692/7529377/59dcafb0e8a1/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7692/7529377/59dcafb0e8a1/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7692/7529377/59dcafb0e8a1/fx1_lrg.jpg

相似文献

1
Remdesivir and COVID-19.瑞德西韦与新型冠状病毒肺炎
Lancet. 2020 Oct 3;396(10256):953-954. doi: 10.1016/S0140-6736(20)32019-5.
2
Remdesivir and COVID-19.瑞德西韦与新型冠状病毒肺炎
Lancet. 2020 Oct 3;396(10256):953. doi: 10.1016/S0140-6736(20)32020-1.
3
Remdesivir and COVID-19.瑞德西韦与新型冠状病毒肺炎
Lancet. 2020 Oct 3;396(10256):952. doi: 10.1016/S0140-6736(20)32021-3.
4
Remdesivir and COVID-19: What are the implications for Africa?瑞德西韦与2019冠状病毒病：对非洲有何影响？
S Afr Med J. 2020 May 7;110(6):12942.
5
[Remdesivir for patients with COVID-19].[瑞德西韦用于新型冠状病毒肺炎患者]
Internist (Berl). 2020 Aug;61(8):869-872. doi: 10.1007/s00108-020-00836-7.
6
Arguments in favour of remdesivir for treating SARS-CoV-2 infections.支持瑞德西韦治疗新型冠状病毒感染的论据。
Int J Antimicrob Agents. 2020 Apr;55(4):105933. doi: 10.1016/j.ijantimicag.2020.105933. Epub 2020 Mar 6.
7
Efficacy of Remdesivir in COVID-19.瑞德西韦治疗新型冠状病毒肺炎的疗效
JAMA. 2020 Sep 15;324(11):1041-1042. doi: 10.1001/jama.2020.16337.
8
COVID-19 Therapeutics: Making Sense of It All.
AACN Adv Crit Care. 2020 Sep 15;31(3):239-249. doi: 10.4037/aacnacc2020792.
9
Pulmonary administration of remdesivir in the treatment of COVID-19.瑞德西韦肺部给药治疗新型冠状病毒肺炎
AAPS J. 2020 Sep 17;22(6):121. doi: 10.1208/s12248-020-00506-4.
10
Remdesivir for the Treatment of Covid-19 - Preliminary Report.瑞德西韦治疗新型冠状病毒肺炎——初步报告
N Engl J Med. 2020 Sep 3;383(10):993-994. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.

引用本文的文献

1
The pharmacogenomic landscape in the Chinese: An analytics of pharmacogenetic variants in 206,640 individuals.中国人的药物基因组学概况：对206,640名个体的药物遗传变异分析
Innovation (Camb). 2025 Jan 18;6(2):100773. doi: 10.1016/j.xinn.2024.100773. eCollection 2025 Feb 3.
2
Unveiling the Antiviral Capabilities of Targeting Human Dihydroorotate Dehydrogenase against SARS-CoV-2.揭示靶向人类二氢乳清酸脱氢酶对严重急性呼吸综合征冠状病毒2的抗病毒能力。
ACS Omega. 2024 Feb 28;9(10):11418-11430. doi: 10.1021/acsomega.3c07845. eCollection 2024 Mar 12.
3
Clinical evolution and mortality of critically ill patients with SARS-CoV-2 pneumonia treated with remdesivir in an adult intensive care unit of Paraguay.

本文引用的文献

1
Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.瑞德西韦治疗新冠病毒病-初步报告。回复。
N Engl J Med. 2020 Sep 3;383(10):994. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.
2
The mutational constraint spectrum quantified from variation in 141,456 humans.从 141456 名人类个体的变异中量化的突变约束谱。
Nature. 2020 May;581(7809):434-443. doi: 10.1038/s41586-020-2308-7. Epub 2020 May 27.
3
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.瑞德西韦治疗成人重症 COVID-19 的随机、双盲、安慰剂对照、多中心临床试验。
巴拉圭成人重症监护病房中使用瑞德西韦治疗的严重急性呼吸综合征冠状病毒 2 型肺炎患者的临床演变和死亡率。
BMC Infect Dis. 2024 Jan 2;24(1):37. doi: 10.1186/s12879-023-08917-2.
4
Xuanfei Baidu decoction in the treatment of coronavirus disease 2019 (COVID-19): Efficacy and potential mechanisms.宣肺败毒汤治疗新型冠状病毒肺炎（COVID-19）：疗效与潜在机制
Heliyon. 2023 Aug 19;9(9):e19163. doi: 10.1016/j.heliyon.2023.e19163. eCollection 2023 Sep.
5
Current state-of-the-art and potential future therapeutic drugs against COVID-19.针对新型冠状病毒肺炎的当前最先进技术及潜在的未来治疗药物。
Front Cell Dev Biol. 2023 Aug 25;11:1238027. doi: 10.3389/fcell.2023.1238027. eCollection 2023.
6
COVID-19: An Overview of SARS-CoV-2 Variants-The Current Vaccines and Drug Development.新型冠状病毒肺炎（COVID-19）：严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）变异株概述——当前疫苗和药物研发进展。
Biomed Res Int. 2023 Aug 29;2023:1879554. doi: 10.1155/2023/1879554. eCollection 2023.
7
Potential herb‒drug interactions between anti-COVID-19 drugs and traditional Chinese medicine.抗新冠病毒药物与中药之间潜在的药草-药物相互作用。
Acta Pharm Sin B. 2023 Jun 5;13(9):3598-637. doi: 10.1016/j.apsb.2023.06.001.
8
Natural Product-Based Screening for Lead Compounds Targeting SARS CoV-2 M.基于天然产物筛选针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）M的先导化合物
Pharmaceuticals (Basel). 2023 May 19;16(5):767. doi: 10.3390/ph16050767.
9
Assessment of the potential value of combining western medicine therapies with traditional chinese medicine in the treatment of COVID-19: Mechanistic perspectives.评估中西医结合治疗 COVID-19 的潜在价值：机制观点。
Technol Health Care. 2023;31(S1):169-184. doi: 10.3233/THC-236015.
10
In silico analysis of SARS-CoV-2 proteins as targets for clinically available drugs.计算机模拟分析 SARS-CoV-2 蛋白作为临床可用药物的靶点。
Sci Rep. 2022 Mar 29;12(1):5320. doi: 10.1038/s41598-022-08320-y.
Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29.
4
The 2019 novel coronavirus resource.2019新型冠状病毒资源
Yi Chuan. 2020 Feb 20;42(2):212-221. doi: 10.16288/j.yczz.20-030.
5
DrugBank 5.0: a major update to the DrugBank database for 2018.DrugBank 5.0：2018 年 DrugBank 数据库的重大更新。
Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.